ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1135

Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1137

Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1406

Development and Functional Characterization of Salivary Gland Organoids to Investigate Sjögren’s Disease

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1255

Development and Validation of a Brief Measure of Uncertainty Among Patients with Vasculitis and Other Rheumatic Diseases

Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1066

Development of a Pharmacy-Led Intervention to Improve Osteoporosis Screening in VA Community-Based Outpatient Clinics

Measures & Measurement of Healthcare Quality Poster

10:30AM-12:30PM: Abstract Number: 1179

Development of an Optimal Physiotherapy Intervention to Reduce Stiffness Following Knee Joint Replacement

Orthopedics, Low Back Pain, & Rehabilitation – ACR/ARP Poster

10:30AM-12:30PM: Abstract Number: 1351

Development of Noninvasive Assessment Technology for Rheumatoid Arthritis Based on Contact Property Measurements

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1287

Development of the Academy for Workforce Advancement to Enrich Rheumatology Diversity

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1403

Development, Validation and Clinical Use of Health-Related Behaviour Health Fitness Questionnaire (HR-BHF) in Indian (Asian) Subjects Attending a Community Rheumatology Center

Research Methodology Poster – ARP

10:30AM-12:30PM: Abstract Number: 1517

Diagnostic Performance of Anti-dsDNA Antibodies in Pleural, Ascitic and Pericardial Fluid for Lupus Serositis: Experience of a Tertiary Center in Mexico

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1516

Diagnostic Performance of Anti-ribosomal P Antibodies in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus with Diffuse Central Nervous System Manifestations. Experience in a Tertiary Center in Mexico

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1432

Diagnostic Performance of Mayor Salivary Gland Ultrasound for Diagnosis of Sjögren’s Syndrome in Routine Clinical Practice

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1199

Diclofenac Sodium 1% Gel Improves Physical Function in the Performance of Important Activities of Daily Living in Patients with Hand or Knee Osteoarthritis

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 1459

Dietary Modification and Intermittent Fasting Are Common in Patients with Axial Spondylarthritis and May Lead to Reduced Inflammatory Activity

SpA Including PsA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1109

Differences Between Correlation and Causal Inference in Detecting Predictors of Undefined Crystal Arthropathy in Women

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].